NAD+ Nasal Spray in Los Angeles: What Patients Should Know

NAD+ nasal spray is a compounded preparation that delivers nicotinamide adenine dinucleotide through the nasal mucosa, a route some clinicians use for patients pursuing cellular-energy and cognitive-wellness goals. In Los Angeles, candidacy is determined by a licensed clinician through a telehealth review. The preparation is not FDA-approved to treat any condition and is offered only as general wellness support.

For Los Angeles patients searching for a clinician-supervised NAD+ nasal spray option, the practical questions are usually the same: what does NAD+ actually do inside the body, what does the published research support, and how does a clinician decide whether a compounded nasal formulation is reasonable to try? This piece walks through the underlying biology, the human-trial evidence, and the questions worth bringing to a telehealth visit.

What NAD+ Actually Does Inside the Cell

Nicotinamide adenine dinucleotide is a coenzyme present in every living cell. It shuttles electrons through mitochondrial respiration, regulates DNA repair through the PARP enzyme family, and activates the sirtuin family of deacetylases that govern metabolic and stress-response gene programs (Imai & Guarente, npj Aging 2014). Cellular NAD+ pools are not static — they are continuously consumed and regenerated, and the balance between consumption and biosynthesis is what concentration measurements actually reflect.

Tissue NAD+ levels decline measurably with age. In skeletal muscle, skin, brain, and liver, concentrations drop roughly 10–25% per decade after age 40, with substantial individual variation (Massudi et al., PLoS ONE 2012). That decline correlates with reduced mitochondrial function, but causation has been harder to prove. The hypothesis driving most NAD+ research is that restoring intracellular NAD+ may support pathways that get sluggish with aging — not that NAD+ supplementation reverses aging itself.

That hypothesis is testable, and several precursor molecules — nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and NAD+ itself — have been studied in humans as ways to raise blood and tissue NAD+ pools.

What the Research Shows on NAD+ Precursors

The strongest human data so far is on oral NR. In a randomized, placebo-controlled crossover trial, Martens and colleagues showed that 1,000 mg of NR daily for six weeks safely roughly doubled blood NAD+ levels in healthy middle-aged and older adults (Martens et al., Nature Communications 2018). The same group later reported modest reductions in systolic blood pressure in a subset of participants, though the trial was not powered for clinical outcomes.

A more recent trial in prediabetic postmenopausal women found that 250 mg of NMN for 10 weeks improved muscle insulin sensitivity by roughly 25%, an effect comparable to clinically meaningful interventions (Yoshino et al., Science 2021). The NADPARK trial in early Parkinson's disease showed that NR raised cerebral NAD+ as measured by MR spectroscopy and was associated with mild clinical improvement, though the study was small and exploratory (Brakedal et al., Cell Metabolism 2022).

Two important caveats. First, all of these trials studied oral precursors, not nasally delivered NAD+ itself, so direct extrapolation is not appropriate. Second, none of these endpoints were hard clinical outcomes — they were biomarkers of NAD+ metabolism. Whether elevating NAD+ translates into measurable longevity, cognition, or recovery benefits at the population level remains an open question that the field has not yet answered.

Why the Intranasal Route Is of Interest

The nasal mucosa is a thin, highly vascular membrane sitting above an olfactory pathway that connects directly to the central nervous system, partially bypassing first-pass hepatic metabolism. Pharmacokinetic reviews of intranasal drug delivery have shown that some small molecules and peptides can achieve faster systemic exposure and, in some cases, modest CNS penetration via this route (Lochhead & Thorne, Advanced Drug Delivery Reviews 2012).

Whether NAD+ as a molecule meaningfully reaches the brain via the nose is, candidly, not yet established in published clinical trials. Compounded nasal NAD+ preparations are used by some clinicians as a more convenient self-administered option for patients who would otherwise be considering intravenous infusions for general wellness support. A clinician who prescribes a nasal preparation generally frames it as one piece of a broader plan that includes sleep, training load, alcohol moderation, and lab follow-up — not as a replacement for those fundamentals.

How a Clinician Evaluates a Candidate

A telehealth provider reviewing a patient for compounded intranasal NAD+ typically considers several factors:

• Goals and expectations. The conversation starts with what the patient is trying to support — energy, cognitive sharpness, recovery, or general wellness — and whether published evidence offers any reasonable basis for the request.
• Medical history and medications. Active malignancy, certain liver conditions, pregnancy or lactation, and significant nasal pathology (chronic sinusitis, recent nasal surgery, deviated septum with prior intervention) are common reasons to defer or decline.
• Prior NAD+ exposure. Patients who have used IV NAD+ or oral NAD+ precursors usually have a clearer sense of personal tolerability.
• Realistic framing. A careful clinician sets expectations based on what the published research does and doesn't support, and explicitly notes that biomarker improvement is not the same as a clinical benefit.

If the clinician determines the patient is a reasonable candidate, they may discuss the clinician-evaluated NAD+ nasal program at Body Good Men as one option that connects patients to a licensed prescriber and a vetted partner pharmacy.

The Los Angeles Context

Los Angeles is among the most active markets in the country for cellular-wellness peptides, partly because the city's training and longevity culture pushes patients toward newer modalities earlier than the national average. That early-adoption pattern can cut both ways. On one hand, patients arriving at a telehealth visit in West LA, Silver Lake, or Manhattan Beach are often well-read and clear about goals. On the other, expectations can outrun the evidence base, and a careful clinician will distinguish what is documented in peer-reviewed literature from what is documented in podcasts and social feeds.

A few LA-specific considerations come up in clinical conversations:

• Climate and dehydration. Year-round outdoor training in dry valley and canyon air can affect nasal mucosa irritation; some patients find nasal preparations less comfortable in dry seasons.
• Travel cadence. Patients flying weekly between LA and other markets sometimes prefer a self-administered option to in-clinic IV infusions, simply for logistics.
• Combined regimens. Many LA patients are simultaneously evaluating peptides such as sermorelin, injectable NAD+, or B-complex therapies; a clinician will want to map the full stack to reduce redundancy.

None of these alters the fundamentals — eligibility is decided at the visit — but they are worth raising at intake when patients evaluate a telehealth NAD+ nasal program suited to LA logistics.

What to Ask Your Provider

Before starting any compounded NAD+ regimen, a useful set of questions includes:

1. What baseline labs, if any, are appropriate before starting?
2. Given my goals, is there published research evidence — not anecdote — supporting nasal NAD+ specifically over oral precursors or IV?
3. What side effects should I watch for, and when do you want me to call?
4. How long do you typically reassess before deciding whether to continue, taper, or stop?
5. Are there interactions with other peptides, medications, or supplements I'm using?

A clinician who answers those questions clearly, and who is willing to say "we don't fully know yet" where the evidence is thin, is the kind of provider worth working with. Patients exploring compounded NAD+ nasal preparations should expect that conversation, not a sales pitch.

Frequently Asked Questions

Is NAD nasal spray FDA-approved?

No FDA-approved NAD+ nasal spray exists for any clinical indication. Compounded preparations are made by licensed compounding pharmacies for individual patients based on a prescription from a licensed clinician. Compounded products are regulated differently than mass-market FDA-approved drugs and should be obtained only through a clinician-supervised pathway with a vetted pharmacy partner that complies with applicable state and federal compounding standards.

How does NAD nasal spray work?

The preparation delivers nicotinamide adenine dinucleotide across the nasal mucosa. The proposed advantage of intranasal delivery is convenience and the potential, supported by general intranasal-pharmacology research, for partial CNS exposure via the olfactory pathway. Whether intranasal NAD+ raises tissue NAD+ comparably to IV infusions or oral precursors has not been established in published peer-reviewed clinical trials.

Who is a candidate for NAD nasal spray in Los Angeles?

Candidacy is determined by a licensed clinician during a telehealth visit, regardless of whether the patient lives in LA or anywhere else in California. Generally, healthy adults pursuing wellness or recovery goals without contraindications such as active cancer, significant nasal pathology, pregnancy, or lactation may be considered. The clinician evaluates goals, medical history, current medications, and realistic expectations before deciding.

Are there side effects from intranasal NAD+?

Tolerability data on compounded intranasal NAD+ comes mostly from clinical experience rather than randomized trials. Patients sometimes report nasal irritation, mild facial flushing, or transient headache, particularly at the start. Anyone experiencing persistent burning, nosebleeds, or systemic symptoms should stop the preparation and contact their clinician. Adverse events from any compounded product can also be reported through the FDA MedWatch system.

How is NAD nasal spray different from NAD+ injections?

Both forms are compounded and clinician-prescribed. Injectable NAD+ is delivered subcutaneously or intramuscularly, while the nasal preparation uses the nasal mucosa for absorption. The injectable route has more pharmacokinetic precedent in clinical use; the nasal route is preferred by some patients for self-administration and travel convenience. A clinician helps weigh which form makes more sense for an individual patient's goals and tolerance.

Talking to a Clinician

If you're considering NAD+ nasal preparations and want to know whether they're appropriate for you, talk to a licensed clinician. The NAD+ Nasal Spray program at Body Good Men connects you with a US-licensed clinician who reviews your eligibility and, if appropriate, prescribes through our partner pharmacy.

Important Disclosure

men.joinbodygood.com is operated as an affiliate of Body Good Studio LLC and is a whitelabel certified partner of Leg Up Rx. men.joinbodygood.com does not provide medical services, prescribe medications, or maintain patient records. All clinical evaluations, prescription decisions, and medication fulfillment are handled by licensed medical and pharmacy partners through Leg Up Rx. This article is for general informational purposes only and is not medical advice. Talk to a licensed healthcare provider before starting any treatment. Eligibility for any medication is determined solely by a licensed clinician.